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Abstract
Objective: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative dis-
ease in which glia are central mediators of motor neuron (MN) death. Since
multiple cell types are involved in disease pathogenesis, the objective of this
study was to determine the benefit of co-targeting independent pathogenic
mechanisms in a familial ALS mouse model. Methods: Recently, our laboratory
identified that ALS microglia induce MN death in an NF-jB-dependent mecha-
nism. We also demonstrated that a single, post-natal, intravenous injection of
adeno-associated viral vector serotype 9 encoding a shRNA against mutant
SOD1 is able to traverse the blood–brain barrier of ALS mice and reduce
SOD1-expression in astrocytes and MNs. Reducing mutant SOD1 in MNs and
astrocytes led to a robust increase in survival. To evaluate the benefit of co-tar-
geting multiple cell types in ALS, we combined microglial NF-jB suppression
with SOD1 reduction in astrocytes and MNs. Results: Targeting both astrocytes
and microglia resulted in an additive increase in survival and motor function
by delaying both onset and progression. Strikingly, targeting all three cell types
(astrocytes, motor neurons [MNs], and microglia) resulted in an additive
increase in lifespan and motor function, with maximum survival reaching
204 days, 67 days longer than the mean survival of untreated control animals.
Interpretation: Our data suggest that a combinatorial approach co-targeting
different pathogenic mechanisms in independent cell types is a beneficial thera-
peutic strategy for ALS.
Introduction
Mounting evidence suggests multiple cell types are
involved in the devastating loss of MNs in amyotrophic
lateral sclerosis (ALS). Seminal studies utilizing chimeric
mice containing a mixture of SOD1-G93A and nontrans-
genic cells, demonstrate that animals with greater num-
bers of normal, nontransgenic cells develop a slower, less
severe ALS phenotype and survive longer.1 Interestingly,
nontransgenic MNs in close-proximity to mutant SOD1-
expressing non-neuronal cells exhibit neuronal pathology,
suggesting that non-neuronal cells can induce MN dam-
age in a non-cell autonomous manner.1
Conditional deletion of the mutant SOD1 gene in spe-
cific cell lineages provided evidence that individual cell-
types mediate different aspects of disease. For example,
reducing mutant SOD1 in MNs in the slow-progressing
SOD1-G37R mouse delays disease onset and early disease
progression.2 However, reducing mutant SOD1 in glial
fibrillary acidic protein (GFAP)-expressing astrocytes or
CD11b-positive myeloid cells does not alter disease onset
but slows disease progression.2,3 Collectively, these data
suggest that mutant SOD1 damage in MNs dictates onset
and early progression, and astrocytes and microglia con-
tribute to the rate at which disease progresses.4,5
While these genetic studies provide a proof-of-principle
for the cell types involved, the therapeutic potential of
SOD1 reduction was not evaluated until recently. Our
laboratory demonstrated that postnatal reduction of
mutant SOD1 in MNs or astrocytes utilizing a shRNA
targeting mutant SOD1 extends survival in both SOD1-
G93A and SOD1-G37R mice.6 To deliver the shRNA
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construct, we performed single intravenous injections of
adeno-associated viral vector serotype 9 (AAV9), which
has the unique ability to traverse the blood–brain barrier
and induce transgene expression throughout the brain
and spinal cord. Injection of AAV9 into neonates at post-
natal day one (p1) results in robust transduction of the
spinal cord with about 60% of ChAT-positive MNs and
30% of GFAP-positive astrocytes expressing the trans-
gene.7 When AAV9 is injected intravenously into adult
mice, the viral tropism shifts from neuronal to astrocytic
transduction, with 90% of transgene-positive cells co-
expressing astrocytic markers such as GFAP and EAAT2.8
Reducing mutant SOD1 predominantly in astrocytes by
injecting AAV9-shRNA-SOD1 at p21 extends survival in
the SOD1-G93A mouse model by delaying disease pro-
gression. Delivering AAV-shRNA-SOD1 at p1 reduces
mutant SOD1 predominantly in MNs and astrocytes and
increases median lifespan by about 51 days.6
Despite the robust transduction of AAV9 and reduction
of mutant SOD1 in MNs and astrocytes, it was not suffi-
cient to completely hinder the progression in ALS mice.
It is likely that other cell types that are not targeted effi-
ciently with AAV9, such as microglia, are still able to
induce MN death.
We previously demonstrated that microglia mediate
MN death via NF-jB in the SOD1-G93A mouse model
and dampening NF-jB activation in myeloid cells delayed
disease progression by 47%. To transgenically inhibit NF-
jB in microglia in SOD1-G93A mice, we mated SOD1-
G93A mice to mice with conditional mutants of IKKb
(IKKb flox/flox) that express cre recombinase under the
c-fms (CSF1R).10 In these mice, CSF-1R is expressed
throughout the mononuclear phagocyte system, but only
microglia express CSF-1R in the postnatal mouse
brain.10–13 Therefore, we hypothesized that a combinato-
rial approach involving viral-mediated SOD1 suppression
in MNs and astrocytes and transgenic NF-jB inhibition
in microglia would lead to a greater increase of survival
in SOD1-G93A mice.
Materials and Methods
Transgenic mice
All procedures were performed in accordance with the
United States Public Health Service’s Policy on Humane
Care and Use of Laboratory Animals, and the Institu-
tional Animal Care and Use Committee of the Research
Institute at Nationwide Children’s Hospital approved
these studies. Animals were housed under light:dark
(12:12 h) cycle and provided with food and water ad libi-
tum. Transgenic male B6SJ/L(SOD1-G93A)1Gur/J mice
(JacksonLaboratory, Bar Harbor, ME USA) were used for
breeding with other transgenic lines. As previously
described, homozygous IKKbflox/wt; CSF1R-cre+ mice dis-
play severe immune dysfunction, chronic eye infections,
and enlarged spleens, so we evaluated heterozygous
mice.10 SOD1-G93A; IKKbflox/wt; CSF-1R-icre were gener-
ated as previously described by breeding SOD1-G93A
mice to C57BL/6 CSF-1R-cre (Jackson) mice that had
been bred to IKKbflox/flox mice.9 SOD1-G93A; IKKbflox/wt;
CSF1R-cre+ and SOD1-G93A; IKKbflox/wt; CSF1R-cre
mice are abbreviated CSF1R-cre+ and CSF1R-cre,
respectively. SOD1 transgene copy number was confirmed
for all study animals by quantitative real-time polymerase
chain reaction.
Immunoblot analysis
Lumbar spinal cord tissues were homogenized in Tissue
Protein Extraction Reagent (Pierce, Rockford, IL, USA)
with EDTA, Complete protease inhibitor (Roche, Indiana-
polis, IN, USA) and Phospho-STOP (Roche). The samples
were run on NuPAGE Novex 4-12% Bis-Tris polyacril-
amide gels and transferred to a PVDF membrane (Life
Technologies, Carlsbad, CA, USA). Blots were blocked in
5% milk powder, 0.5% BSA in PBS-Tween for 1 h, and
then incubated for overnight at 4°C with primary anti-
body. Primary antibodies (all Cell Signaling, Danvers,
MA, USA): Human SOD1 (1:750), phospho-p65 (1:500),
p65 (1:500), b-Actin (1:1000). Bound primary antibody
was detected by horseradish peroxidase conjugated sec-
ondary antibody (Jackson ImmunoResearch, West Grove,
PA, USA) followed by chemiluminescence detection (ECL
Western Blot Substrate, Pierce).
Immunohistochemistry
Animals were deeply anesthetized with a lethal dose of
xylazene/ketamine and perfused transcardially with saline,
then with 4% paraformaldehyde. Spinal cords were sec-
tioned 40 lm thick using a vibrating blade microtome
(Leica Microsystems, Wetzlar, Germany). Sections were
incubated for 2 h at room temperature in TBS+ 1% Tri-
ton-X + 10% donkey serum. Samples were incubated for
72 h at 4°C with primary antibodies, followed by 2 h
incubation at RT with secondary antibodies. Primary
antibodies: green fluorescent protein (GFP) (Abcam,
1:400), GFAP (Abcam, Cambridge, UK, 1:500), Iba-1
(Wako, Richmond, VA, USA, 1:400), ChAT (Millipore,
Darmstadt, Germany, 1:50). All images were captured on
a Zeiss confocal microscope (Carl Zeiss Microscopy,
Thornwood, NY). For quantification of transduced MNs
and astrocytes, lumbar spinal cords were sectioned
40 lm thick from the end of thoracic level 14 to sacral
level 1.
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Viral vectors
The shRNA construct targeting human SOD1 was gener-
ated and obtained as previously described from the Life
Technologies design tool.6 The shRNA sequence was
cloned into pSilencer 3.1 (Genscript, Piscataway, NJ, USA)
under the human H1 promoter and tested for human
SOD1 reduction in vitro. The shRNA and H1 promoter
was further cloned into an AAV vector with GFP under the
chicken b-actin promoter. Self-complementary AAV9-
SOD1-shRNA was produced by transient transfection pro-
cedures using a double-stranded AAV2-ITR-based CB-GFP
vector, with a plasmid encoding the Rep2Cap9 sequence,
along with an adenoviral helper plasmid pHelper (Strata-
gene, Santa Clara, CA) in HEK293 cells.
Injections
For neonatal mouse injections, postnatal day 1 (p1)
SOD1-G93A pups were used. Total volume of 50 lL con-
taining 5 9 1011 (3.6 9 1014 vg/kg) DNase-resistant viral
particles of AAV9-SOD1-shRNA (Virapur LLC, San
Diego, CA) was injected through temporal vein as previ-
ously described.8 A successful injection was verified by
noting blanching of the vein. Pups were returned to their
cage after the injection. For adult, postnatal day 21 (p21)
tail vein injections, animals were placed in a restraint that
positioned the tail in a lighted, heated groove. The tail
was swabbed with alcohol and then injected intravenously
with AAV9-SOD1-shRNA. SOD1-G93A mice were
injected with 200 lL viral solution containing 2 9 1012
DNase-resistant viral particles, for an average dose of
1.7 9 1014 vg/kg. It is important to note that all cohorts
of mice were generated simultaneously for comparison,
and p1 and p21 data are plotted separately for clarity.
Therefore, the uninjected control groups are the same in
Figures 2–4 and 7–9.
Disease scoring and behavior analysis
Disease onset and progression was determined retrospec-
tively from animal mass data. Onset is defined at the
stage mice reach peak body mass. Progression is defined
as the time from peak body mass until death. Testing of
motor function using a rotarod device (Columbus Instru-
ments, Columbus, OH) began at 60 days of age. Each ses-
sion consisted of three trials that were averaged on the
elevated accelerating rotarod beginning at 5 rpm/min
measuring the time the mouse was able to remain on the
rod. Grip strength measurements for hindlimb were tested
weekly using a grip strength meter (Columbus Instru-
ments). Each session consisted of three tests per animal
and values were averaged.
Results
To target both astrocytes and microglia, we injected
SOD1-G93A; IKKbflox/wt; CSF1R-cre+ (abbreviated
CSF1R-cre+) mice intravenously with AAV9-SOD1-
shRNA at postnatal day 21. Along with the SOD1-shRNA,
the AAV9 vector encodes contains GFP allowing us to
visualize AAV9 transduction. Shown by immunohisto-
chemistry (Fig. 1A), we observed that 90% of transduced
cells were astrocytes in the lumbar spinal cord of 100-
day-old mice, similar to levels we previously reported.6,8
Figure 1. AAV9 transduces astrocytes when injected in adult CSF1R-
cre+ and cre SOD1-G93A mice. (A) Immunohistochemistry and
quantification of lumbar spinal cords of SOD1-G93A; IKKbF/wt; CSF1R-
cre mice (left) and SOD1-G93A; IKKbF/wt; CSF1R-cre+ mice (right)
injected at postnatal day 21 with AAV9-SOD1-shRNA expressing GFP.
(B) Quantification of transduced (GFP+) cells at postnatal day 100
shows no significant difference in the mean percent of transduced
astrocytes (GFP+/GFAP+) between CSF1R-cre (72.2  0.7%) and
CSF1R-cre+ mice (73.2  2.5%). Few motor neurons were
transduced at p21 in both CSF1R-cre (9.6  0.5%) and CSF1R-cre+
mice (10.1  0.6%), determined by counting transduced cells (GFP)
co-labeled ChAT+ motor neurons throughout the lumbar spinal cord.
Lumbar spinal cords from three animals per group were analyzed.
Scale bars indicate 100 lm (left) and 50 lm (right). AAV9, adeno-
associated viral vector serotype 9; GFP, green fluorescent protein.
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Quantification of GFP+ cells indicated the intravenous
injection of AAV9-shRNA-SOD1 targeted about 70% of
total GFAP-positive astrocytes and 10% of ChAT+ MNs
(Fig. 1B).
As expected, median survival of uninjected CSF1R-cre+
mice was 20 days longer than uninjected CSF1R-cre lit-
termates. P21 injected CSF1R-cre mice had an increased
median survival of 23 days compared to uninjected con-
trols. Strikingly targeting both NF-jB activation in micro-
glia and reducing SOD1 in astrocytes, extended median
survival to 167 days compared to 137 days in untreated,
control mice (Fig. 2A). This amounted to a 25% increase
in mean survival in p21 injected CSF-1R-cre+ mice
(169.8  2.2 days) compared to uninjected CSF-1R-cre
mice (136.3  0.9 days) (Fig. 2B).
Consistent with the increase in lifespan, body mass was
maintained longer in injected mice and uninjected
CSF1R-cre+ mice compared to uninjected CSF1R-cre
mice (Fig. 3A). Disease onset, which is retrospectively
defined as the age at which the mouse reaches peak
weight, was not altered in uninjected CSF1R-cre+ mice
compared to uninjected controls (104.7  2.5 and
104.2  1.0 days, respectively). However, p21 injected
CSF1R-cre mice exhibited a slight delay in disease onset
(108.9  2.1 days), most likely attributed to the small
amount of MNs transduced. Surprisingly, onset was sig-
nificantly delayed in p21 CSF1R-cre+ mice
(127.6  1.9 days), about 23 days longer than uninjected
controls (Fig. 3B). It is important to note that similar
numbers of MNs (about 10% of total ChAT+ cells) were
transduced with p21 injections of AAV9 in CSF1R-cre+
and CSF1R-cre mice.
Disease progression, measured from time at which the
animal reaches peak weight until death, was prolonged in
all treated groups compared to uninjected CSF1R-cre
mice (Fig. 3C). However, targeting both astrocytes and
microglia did not result in an additive extension in pro-
gression. Disease progression of CSF1R-cre+ p21 injected
mice averaged 42.3  2.6 days compared to
48.6  2.6 days in p21 injected CSF1R-cre and
51.44  2.7 days for uninjected CSF1R-cre+ mice
(Fig. 3C). We hypothesize the additive increase in survival
was distributed between early and late phases of disease;
thus we did not observe a preferential additive increase in
disease onset or progression.
Motor performance measured by accelerating rotarod
(Fig. 4A), forelimb (Fig. 4B), and hindlimb grip strength
(Fig. 4C) was improved in all conditions in which astro-
cytes and/or microglia were targeted. CSF1R-cre+ unin-
jected mice exhibited improved rotarod performance
during disease progression compared to CSF1R-cre
uninjected littermates (Fig. 3A). Similar to the late-stage
differences between uninjected CSF1R-cre+ and CSF1R-
cre mice, p21 injected groups (CSF1R-cre+ and CSF1R-
cre) exhibited improved motor performance until the
late-stage of disease (Fig. 4A–C). These data suggest tar-
geting microglia and astrocytes leads to an additive
increase in survival and motor function in SOD1-G93A
mouse model.
Since we observed an additive increase in median sur-
vival by targeting both astrocytes and microglia in the
SOD1-G93A mice, we hypothesized that reducing levels
of mutant SOD1 in MNs and astrocytes would lead to an
Figure 2. Targeting microglia and astrocytes leads to additive
increase in survival in SOD1-G93A mice. SOD1-G93A; IKKbF/wt;
CSF1R-cre mice and SOD1-G93A; IKKbF/wt; CSF1R-cre+ mice
received a single intravenous injection of AAV9-SOD1-shRNA at
postnatal day 21. Injected CSF1R-cre (gray) and CSF1R-cre+ (green)
mice and uninjected controls (red and blue) were monitored up to
end-stage of disease. (A) Kaplan–Meier survival analysis of the
probability of survival as a function of age in SOD1-G93A; IKKbF/wt;
CSF1R-cre (shown in red, n = 33), SOD1-G93A; IKKbF/wt; CSF-1R-
cre+ mice (blue, n = 13), CSF1R-cre mice injected with SOD1-shRNA
at p21 (gray, n = 14), and CSF1R-cre+ mice injected with AAV9-
SOD1-shRNA at p21 (green, n = 13). Median survival: uninjected
CSF1R-cre = 137 days, uninjected CSF-1R-cre+ = 157 days, CSF1R-
cre p21 injected = 160 days, CSF1R-cre+ p21 injected = 168 days.
(B) Mean survival of mice from uninjected CSF1R-
cre = 136.9  0.9 days, uninjected CSF-1R-cre+ = 157.9 
1.8 days, CSF1R-cre p21 injected = 158.1  1.8 days, CSF1R-cre+
p21 injected = 169.8  2.2 days. AAV9, adeno-associated viral vector
serotype 9.***p < 0.001; ****p < 0.0001.
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additional increase survival in CSF1R-cre+ mice. To effi-
ciently target MNs and astrocytes with AAV9, we injected
a cohort of mice with AAV9-SOD1-shRNA intravenously
at postnatal day 1. It is important to note that all cohorts
of mice were generated simultaneously for comparison,
and p1 and p21 data are plotted separately for clarity. As
shown by immunohistochemistry, GFP can be detected in
both astrocytes and MNs of p1-injected animals (Fig. 5A).
Quantification reveals about 60% of ChAT+ MNs and
40% of astrocytes are transduced when AAV9-shRNA-
SOD1 is injected at p1 (Fig. 5B).
To determine the level of SOD1 suppression between
p21 and p1 injections, we performed immunoblot anal-
yses of end-stage whole-lumbar spinal cord lysate.
Mutant SOD1 was reduced by 50% at end-stage when
AAV9-shRNA-SOD1 was injected at p1 or p21, similar
to our previously findings (Fig. 6A and B).6 No differ-
ence in mutant SOD1 suppression was observed
between CSF1R-cre+ and cre injected mice (Fig. 6A).
To confirm NF-jB inhibition in our CSF1R-cre+ mice,
we performed immunoblot analysis in lumbar spinal
cord homogenate for phosphorylated p65 (phospho-
p65). Phospho-p65 was reduced in end-stage lumbar
spinal cord homogenate of CSF1R-cre+ compared to
cre mice (Fig. 6C).
Strikingly targeting both NF-jB activation in microglia
and reducing SOD1 in MNs and astrocytes (CSF1R-cre+,
p1-shRNA-SOD1) extended median survival to 188 days
compared to 137 days in CSF1R-cre uninjected mice
(Fig. 7A). This amounted to a 38% increase in mean sur-
vival (188.7  1.8 and 136.3  0.9 days) (Fig. 7B). The
longest-lived mouse survived to 204 days of age, one of
the longest extensions in survival ever reported for this
fast-progressing SOD1-G93A mouse model. CSF1R-cre
p1 injected mice had a median survival of 175.5 days,
and had a 27% increase in mean survival compared to
CSF1R-cre uninjected mice (Fig. 7B). These data
demonstrate that heterozygous inhibition of NF-jB
Figure 3. Disease onset and progression are delayed in SOD1-G93A
mice by targeting both astrocytes and microglia. (A) Uninjected
CSF1R-cre+ mice (blue) retained more body mass in late stages of
disease compared to uninjected CSF1R-cre mice (red). P21-treated
mice, both CSF1R-cre (gray) and CSF1R-cre+ (green), maintained
body mass throughout their increased lifespan (B) Onset defined by
peak weight is delayed in CSF1R-cre+; p21 injected mice (green)
compared to all uninjected (blue and green) and CSF1R-cre; p21
injected mice (gray). (C) Disease progression, defined by time from
peak weight until death, is delayed in all mice with either microglia
(blue), astrocytes (gray), or both (green) targeted, compared to
untreated controls (red). ***p < 0.001; ****p < 0.0001.
Figure 4. Motor function is improved in SOD1-G93A mice by
targeting microglia and astrocytes in concert. SOD1-G93A; IKKflox/wt;
CSF1R-cre+; p1 injected mice (green) exhibit improved motor
performance as demonstrated in accelerating rotarod testing (A)
forelimb grip strength (B) and hindlimb grip strength (C). Motor
performance was improved in all treated groups (blue, gray, and
green) compared to untreated controls (red).
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signaling in microglia leads to an additive increase in sur-
vival when combined with SOD1 suppression in MNs
and astrocytes.
Consistent with the increase in lifespan, body mass was
maintained longer in injected mice compared to unin-
jected mice. Interestingly, less mass was lost overall in
both CSF1R-cre+ groups (uninjected and p1 injected)
compared to both CSF1R-cre groups (Fig. 8A).
Although not statistically significant, onset was delayed in
CSF1R-cre+; p1 injected mice compared to CSF1R-cre;
p1 injected mice (134.9  2.3 and 139.1  1.8 days,
respectively) (Fig. 8B). As predicted, disease progression
was prolonged in CSF1R-cre p1 injected mice and
CSF1R-cre+ p1 injected mice (Fig. 8C). Thus, all condi-
tions targeting microglia and/or MNs and astrocytes
resulted in an extension in disease progression.
Motor performance measured by accelerating rotarod,
forelimb and hind limb grip strength was substantially
Figure 5. Injection of AAV9 at postnatal day 1 transduces motor
neurons and astrocytes in CSF1R-cre+ and cre ALS mice. (A)
Immunohistochemistry and quantification of lumbar spinal cords of
SOD1-G93A; IKKbF/wt; CSF1R-cre mice (left) and SOD1-G93A; IKKbF/wt;
CSF1R-cre+ mice (right) injected at postnatal day 1 with AAV9-SOD1-
shRNA expressing GFP. Scale bar indicates 50 lm. (B) Quantification
of transduced (GFP+) cells at postnatal day 100 shows no significant
difference in the mean percent of transduced astrocytes (GFP+/
GFAP+) between CSF1R-cre (40.3  1.7%) and CSF1R-cre+ mice
(36.4  2.0%). Few motor neurons were transduced at p1 in both
CSF1R-cre (62.8  0.3%) and CSF1R-cre+ mice (65.5  3.4%),
determined by counting transduced cells (GFP) co-labeled ChAT+
motor neurons throughout the lumbar spinal cord. Lumbar spinal
cords from three animals per group were analyzed. AAV9, adeno-
associated viral vector serotype 9; ALS, amyotrophic lateral sclerosis;
GFP, green fluorescent protein.
Figure 6. AAV9 shRNA-SOD1 efficiently reduces mutant SOD1
protein in CSF-1R-cre and CSF-1R-cre+ mice. (A) End-stage spinal
cord lysates of SOD1-G93A; IKKbF/wt CSF1R-cre and CSF1R-cre+
mice injected at either p21 or p1 with AAV9-shRNA-SOD1 were
evaluated by immunoblot for levels of mutant human SOD1 protein.
(B) Quantification of (A), hSOD1 normalized to actin. (C) End-stage
lumbar spinal cord lysates were evaluated for NF-jB activation by
probing for phosphorylated-p65 (p-p65). All CSF1R-cre+ mice
exhibited reduced p-p65, indicative of decreased NF-jB activity.
AAV9, adeno-associated viral vector serotype 9. *p < 0.05.
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 81
A. E. Frakes et al. Additive amelioration of ALS
improved in p1-injected mice compared to both unin-
jected groups (Fig. 9A–C). Similar to the late-stage differ-
ences in uninjected CSF1R-cre+ and CSF1R-cre mice,
p1 injected groups (CSF1R-cre+ and CSF1R-cre) exhib-
ited similar motor performance until the late-stage of dis-
ease, when CSF1R-cre+ mice maintained motor function,
which coincided with the longer lifespans. These data sug-
gest a combinatorial approach to target microglia, MNs
and astrocytes confers greatest benefit to motor function
and survival of SOD1-G93A mice.
One of the most striking disease hallmarks that is
shared by patients and rodent models of ALS is gliosis,
characterized by alterations in astrocyte and microglial
morphology. NF-kB inhibition in microglia and SOD1
suppression both independently decrease gliosis.6,10
Therefore, to determine the impact of a combinatorial
treatment on gliosis at disease onset, we analyzed lumbar
spinal cord sections for levels of Iba-1 as an indicator of
microgliosis and GFAP for astrogliosis. We observed a
robust decrease in Iba1 and GFAP levels at 100 days of
age in CSF1R-cre+ mice that were injected with AAV9-
shRNA-SOD1 at either p1 or p21 (Fig. 10). Since gliosis
is an indicator of homeostasis in the spinal cord, these
data suggest disease pathogenesis is substantially delayed
in combinatorial treated mice.
Discussion
Here, we report that co-targeting independent pathologi-
cal mechanisms in different cell types in combination
leads to one of the largest extensions in survival observed
in the high copy number, fast-progressing SOD1-G93A
mouse model of ALS. We previously demonstrated that
NF-jB is upregulated in SOD1-G93A microglia with dis-
ease progression. Heterozygous inhibition of NF-jB
Figure 7. Targeting microglia, astrocytes, and motor neurons leads to
additive increase in survival in SOD1-G93A mice. SOD1-G93A; IKKbF/wt;
CSF1R-cre mice and SOD1-G93A; IKKbF/wt; CSF1R-cre+ mice received
a single intravenous injection of AAV9-SOD1-shRNA at postnatal day 1.
Injected CSF1R-cre (gray) and CSF1R-cre+ (green) mice and
uninjected controls (red and blue) were monitored up to end-stage of
disease. (A) Kaplan–Meier survival analysis of the probability of survival
as a function of age in SOD1-G93A; IKKbF/wt; CSF1R-cre (shown in
red, n = 33), SOD1-G93A; IKKbF/wt; CSF-1R-cre+ mice (blue, n = 13),
CSF1R-cre mice injected with SOD1-shRNA at p1 (gray, n = 8),
and CSF1R-cre+ mice injected with AAV9-SOD1-shRNA at p1 (green,
n = 12). Median survival: uninjected CSF1R-cre = 137 days,
uninjected CSF-1R-cre+ = 157 days, CSF1R-cre p1 injected =
177.5 days, CSF1R-cre+ p1 injected = 185 days. (B) Mean survival of
mice from uninjected CSF1R-cre = 136.9  0.9 days, uninjected
CSF-1R-cre+ = 157.9  1.8 days, CSF1R-cre p1 injected = 177.4
 1.9 days, CSF1R-cre+ p1 injected = 189.1  2.7 days. **p < 0.01;
***p < 0.001; ****p < 0.0001.
Figure 8. Targeting microglia, astrocytes, and motor neurons delays
onset and disease progression in SOD1-G93A mice. (A) Both CSF1R-
cre (gray) and CSF1R-cre+ (green) p1-treated mice maintained body
mass throughout their increased lifespan. Onset (B) and disease
progression (C) was delayed in both CSF1R-cre and CSF1R-cre+; p1
injected mice (gray and green) compared to all uninjected (blue and
green) mice. ***p < 0.001; ****p < 0.0001.
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resulted in a 20-day increase in median survival by delay-
ing disease progression by 47%. We now show that sup-
pressing NF-jB activation in microglia and reducing
mutant SOD1 levels in both astrocytes and MNs extended
median lifespan to 188 days compared to 137 days in
controls. This amounted to a 38% increase in median
survival with maximum survival reaching up to 204 days.
These animals displayed a striking improvement in motor
function compared to untreated controls shown by the
accelerating rotarod test, and forelimb and hindlimb grips
strength. Rotarod performance did not decline in combi-
natorial treated mice until around 180 days of age, nearly
70 days after motor impairment was first detected in
untreated controls.
By combining microglial NF-jB inhibition with SOD1
suppression in astrocytes and MNs, we observed an addi-
tive increase in survival. This suggests that NF-jB activa-
tion in microglia functions independently of SOD1 in
astrocytes and MNs in the pathogenesis of ALS.
Interestingly, we observed a surprising shift in disease
onset when targeting predominantly astrocytes and
microglia, but not MNs. Previous studies suggest that
astrocytes and microglia are not involved in disease onset
but contribute to the rate of disease progression.2–4 As
expected, targeting either glial cell type independently
corroborated previous studies and significantly extended
disease progression but not onset.6,10 Since reducing
mutant SOD1 in MNs delays disease onset and early dis-
ease progression, it is important to note that a small per-
centage of MNs are transduced when AAV9 is injected at
postnatal day 21.6,8 This may account for a 5 day delay in
mean disease onset in CSF1R-cre-negative mice injected
with AAV9-shRNA-SOD1 at p21. However, the number
of GFP-positive MNs was not different between injected
cre-positive and cre-negative mice. Thus, the delay in dis-
ease onset in CSF1R-cre+, p21-injected mice cannot be
attributed to the small percentage of MNs targeted with
AAV9-shRNA-SOD1.
Immunohistochemical analysis of lumbar spinal cords
at 100 days (disease onset of uninjected mice), showed
that all combinatorial-targeted mice had reduced gliosis
to near wild-type levels. We previously demonstrated that
microglial NF-jB inhibition in SOD1-G93A mice slowed
astrogliosis and microglial activation during disease pro-
gression.10 In this study, targeting both astrocytes and
microglia delayed activation from the point of disease
onset. Since glial reactivity is an indicator of homeostasis
in the spinal cord, targeting both astrocytes and microglia
prolonged homeostasis compared to uninjected control
animals. Thus, our data may reveal a more complicated,
unknown interaction between astrocytes and microglia in
early ALS pathogenesis and disease onset. Gene expression
profiling of presymptomatic microglia corroborates
immunohistochemical data, suggesting glial alterations
occur early in SOD1-G93A mice.14,15 This raises the
intriguing question of whether full correction of glial cell
types can rescue or delay degeneration of diseased MNs.
While combinatorial targeting of microglia, astrocytes,
and MNs resulted in a robust increase in survival, ulti-
mately the mice still succumbed to disease. This can be
attributed to several factors. First, we are not removing all
mutant SOD1 from astrocytes and MNs or fully suppress-
ing NF-jB activity in microglia. Despite reducing mutant
SOD1 levels by nearly 50% in the spinal cord, residual
mutant SOD1 eventually leads to paralysis in this high
copy number, aggressive SOD1-G93A strain. We hypothe-
size that similar SOD1 reduction strategies will result in
an even greater increase in survival in strains expressing
lower levels of SOD1 initially, and even in SOD1 patients,
considering patients only harbor one mutant allele. Sec-
ond, targeting a more upstream pathogenic mechanism in
microglia, such as mutant SOD1, will most likely confer
Figure 9. Motor function improves additively in SOD1-G93A mice by
targeting microglia, motor neurons, and astrocytes. SOD1-G93A;
IKKflox/wt; CSF1R-cre+; p1-injected mice (green) exhibit improved
motor performance as demonstrated in accelerating rotarod testing
(A) forelimb grip strength (B) and hindlimb grip strength (C). All
treated groups (blue, gray, and green) showed improved motor
performance over untreated controls (red).
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greater benefit to survival. We hypothesize that synergistic
epistasis between NF-jB and SOD1 might only be
observed if both are suppressed in microglia. Lastly, other
cell types such as oligodendrocytes and NG2+ progenitors
contribute to disease pathogenesis.16,17 Recently, it was
reported that removal of mutant SOD1 in oligodendro-
cyte progenitors delays disease onset and early disease
progression in the slow-progressing SOD1-G37R mouse
model of ALS.16 Interestingly, removing mutant SOD1
selectively from muscle or endothelia did not alter the
disease course in ALS mouse models. However, it is pos-
sible that as treated mice live longer, more subtle cellular
players or potentially new pathological mechanisms may
emerge. Thus, the most efficacious therapeutic approach
is likely to derive from co-targeting multiple pathogenic
mechanisms and cell types.
Cumulative evidence suggests microglial NF-jB may be
a promising therapeutic target for both familial and spo-
radic ALS. For example, several laboratories have con-
firmed NF-jB is activated in glia in both familial and
sporadic ALS patients by immunohistochemistry on post-
mortem tissue samples. Additionally, TDP-43 and FUS
have been shown to be co-activators of NF-jB, and NF-
jB inhibition in transgenic mice overexpressing mutant
TDP-43 ameliorated the disease phenotype.18,19 Further-
more, several other ALS-associated mutations such as
OPTN, p62, and VCP are involved in regulating the NF-
jB pathway and could be involved in pathological NF-jB
activation in microglia23,24,25. Interestingly, the ALS-caus-
ing nonsense and missense mutations in OPTN abolished
the ability of OPTN to inhibit NF-jB signaling.20,21 One
well-characterized function of VCP is to assist in protea-
somal degradation of the NF-jB inhibitor, IjBa.22 Future
studies should determine whether NF-jB activation in
microglia harboring these ALS mutations results in MN
toxicity. However, the inability to easily study human
microglia remains one of the biggest limitations in the
field.
Whether SOD1 is a therapeutic target for sporadic ALS
remains controversial. Recent studies have given rise to
Figure 10. Astrogliosis and microgliosis is delayed in SOD1-G93A mice when multiple pathogenic mechanisms are targeted.
Immunohistochemistry of lumbar spinal cords at 100 days of age shows marked reduction in reactivity of microglia (Iba1, red) and astrocytes
(GFAP, blue) in both p21- and p1-injected mice. GFP transduction of AAV9-shRNA-SOD1 is shown in green. Three animals were analyzed for
each group. Scale bar indicates 200 lm. GFP, green fluorescent protein; AAV9, adeno-associated viral vector serotype 9.
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the hypothesis that wild-type human SOD1 has the
propensity to misfold, aggregate, and trigger pathogenic
pathways similar to those induced by mutant SOD1.26–30
However, conflicting reports fail to detect misfolded
SOD1 in postmortem sporadic tissue.31–33 While no con-
sensus has emerged, the potential that some sporadic ALS
patients could also benefit from AAV9-mediated SOD1
reduction should be investigated. Furthermore, recent
reports demonstrate that AAV9 can readily transduce
MNs and astrocytes in non-human primates.8,34,35 Thus,
as new potential therapeutic targets emerge for sporadic
ALS, AAV9 could be utilized as an efficient tool to
manipulate these cell types.
Taken together, these data provide new insight and a
proof-of-principle that co-targeting multiple pathogenic
mechanisms in independent cell types is a promising ther-
apeutic strategy for ALS. A multipronged strategy has
proved beneficial in treating other diseases and cancers
and should be explored for neurodegenerative diseases
such as ALS.36–39 Thus, future efforts should focus on
generating efficient and specific methods to target indi-
vidual cell types in the brain and spinal cord.
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